The clinical significance of measles: A review

Journal of Infectious Diseases

Volumn 189, Issue SUPPL. 1, 2004, Pages

  Perry, Robert T ^a   Halsey, Neel A ^b  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

BLINDNESS; CAUSE OF DEATH; CLINICAL FEATURE; CROUP; CROWDING; DEATH; DEVELOPED COUNTRY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; ENCEPHALITIS; FATALITY; FEBRILE CONVULSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LARYNGOTRACHEOBRONCHITIS; MALNUTRITION; MEASLES; MORBIDITY; MORTALITY; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; RETINOL DEFICIENCY; REVIEW; SOCIOECONOMICS; SUBACUTE SCLEROSING PANENCEPHALITIS;

EID: 2442500607     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377712     Document Type: Review

References (241)

1. Black FL. Measles antibodies in the population of New Haven, Connecticut. J Immunol 1959; 83:74-83.
2. Hedrich AW. Monthly estimates of the child population "susceptible" to measles, 1900-1931, Baltimore, Maryland. Am J Hyg 1933; 17:613-36.
3. Langmuir AD. Medical importance of measles. Am J Dis Child 1962; 103:224-6.
4. Snyder MJ, McCrumb FR, Bigbee T, Schluederberg AE, Togo Y. Observations on the seroepidemiology of measles. Am J Dis Child 1962; 103:250-1.
5. Measles (rubeola). In: Krugman S, Katz SL, Gershon AA, Wilfert CM, eds. Infectious disease of children. 9th ed. St. Louis: Mosby Year Book, 1992:223-45.
6. Robbins FC. Measles: clinical features. Am J Dis Child 1962; 103: 266-73.
7. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis 1983; 5:477-81.
8. Krugman S. Infectious diseases of children. St. Louis: Mosby, 1958.
9. Scheifele DW, Forbes CE. Prolonged giant cell excretion in severe African measles. Pediatrics 1972; 50:867-73.
10. Morley DC. Measles in the developing world. Proc R Soc Med 1974; 67:1112-5.
11. Koplik HT. The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucosa. Arch Pediatr 1896; 13:918-22.
12. Suringa DW, Bank LJ, Ackerman AB. Role of measles virus in skin lesions and Koplik's spots. N Engl J Med 1970; 283:1139-42.
13. Babbott FL, Gordon JE. Modern measles. Am J Med Sci 1954; 228: 334-61.
14. Chapin CV. Measles in Providence, Rhode Island, 1858-1923. Am J Hyg 1925; 5:635-55.
15. Hope Simpson RE. Infectiousness of communicable diseases in the household (measles, chicken pox, and mumps). Lancet 1952; 2:549-54.
16. Top FH. Measles in Detroit, 1935. I. Factors influencing the secondary attack rate among susceptibles at risk. Am J Public Health 1938; 28: 935-43.
17. Centers for Disease Control. Measles among members of a drum and bugle corps - Arkansas, California, Kansas. MMWR Morb Mortal Wkly Rep 1983; 32:561-2, 567.
18. Centers for Disease Control and Prevention. Interstate measles transmission from a ski resort - Colorado, 1994. MMWR Morb Mortal Wkly Rep 1994; 43:627-9.
19. Centers for Disease Control and Prevention. Measles outbreak among school-aged children - Juneau, Alaska, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:777-80.
20. Ehresmann KR, Hedberg CW, Grimm MB, Norton CA, MacDonald KL, Osterholm MT. An outbreak of measles at an international sporting event with airborne transmission in a domed stadium. J Infect Dis 1995; 171:679-83.
21. Orenstein WA, Irvin J, Jennings MR, et al. Measles in a rural Ohio county. Am J Epidemiol 1980; 111:777-89.
22. Bloch AB, Orenstein WA, Ewing WM, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676-83.
23. Remington PL, Hall WN, Davis IH, Herald A, Gunn RA. Airborne transmission of measles in a physician's office. JAMA 1985; 253:1574-7.
24. Bennett J, Whittle H, Samb B, Cisse B, Simondon F, Aaby P. Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. Int J Epidemiol 1999; 28:147-51.
25. Krugman S, Giles JP, Jacobs AM, Friedman H. Studies with a further attenuated live measles-virus vaccine. Pediatrics 1963; 31:919-28.
26. Krugman S, Giles JP, Jacobs AM, Friedman H. Studies with live attenuated measles-virus vaccine: comparative clinical, antigenic, and prophylactic effects after inoculation with and without gamma-globulin. Am J Dis Child 1962; 103:353-63.
27. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
28. Cherry JD, Feigin RD, Lobes LA Jr, et al. Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study. J Pediatr 1972; 81: 217-30.
29. Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990; 263:2467-71.
30. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353:98-102.
31. Lee MS, Nokes DJ, Hsu HM, Lu CF. Protective titres of measles neutralising antibody. J Med Virol 2000; 62:511-7.
32. Smith FR, Curran AS, Raciti KA, Black FL. Reported measles in persons immunologically primed by prior vaccination. J Pediatr 1982; 101:391-3.
33. Lievano FA, Papania MJ, Helfand RF, et al. Lack of evidence of measles virus shedding in people with inapparent measles virus infections. J Infect Dis 2004; 189(Suppl 1):S165-70.
34. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202:1075-80.
35. Nader PR. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J Pediatr 1968; 72:22-8.
36. Rauh LW, Schmidt R. Measles immunization with killed virus vaccine: serum antibody titers and experience with exposure to measles epidemic. Am J Dis Child 1965; 109:232-7.
37. Polack FP, Auwaerter PG, Lee SH, et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 1999; 5:629-34.
38. Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles [see comments]. Nat Med 2000; 6:776-81.
39. Cherry JD. Measles. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 4th ed. Philadelphia: WB Saunders, 1998: 2054-74.
40. Archibald RW, Weller RO, Meadow SR. Measles pneumonia and the nature of the inclusion-bearing giant cells: a light- and electron-microscope study. J Pathol 1971; 103:27-34.
41. Corbett EU. The visceral lesions in measles, with a report of Koplik spots in the colon. Am J Pathol 1945; 21:905-14.
42. Davidsohn I, Mora JM. Appendicitis in measles. Arch Pathol 1932; 14:757-65.
43. Degen JA. Visceral pathology in measles: a clinico-pathological study of 100 fatal cases. Am J Med Sci 1937; 194:104-11.
44. Denton J. The pathology of fatal measles. Am J Med Sci 1925; 169: 531-43.
45. Herzberg M. Giant cells in the lymphoid tissue of the appendix in the prodromal stage of measles: report of an isolated case. JAMA 1932; 98:139-40.
46. Lucke B. Postmortem findings in measles bronchopneumonia and other acute infections. JAMA 1918; 70:2006-11.
47. Milles G. Measles-pneumonia (with a note on the giant cells of measles). Am J Clin Pathol 1945; 15:334-8.
48. Monif GR, Hood CI. Ileocolitis associated with measles (rubeola). Am J Dis Child 1970; 120:245-7.
49. Roberts GBS, Bain AD. The pathology of measles. J Pathol Bacteriol 1958; 76:111-8.
50. Sheehy TW, Artenstein MS, Green RW. Small intestinal mucosa in certain viral diseases. JAMA 1964; 190:1023-8.
51. Vieth M, Dirshmid K, Oehler U, Helpap B, von Luckner AG, Stolte M. Acute measles gastric infection. Am J Surg Pathol 2001; 25:259-62.
52. Auwaerter PG, Rota PA, Elkins WR, et al. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 1999; 180:950-8.
53. Joffe MI, Sukha NR, Rabson AR. Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. J Clin Invest 1983; 72:971-80.
54. Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE. Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis 2002; 185:1035-42.
55. Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol 2000; 145:905-20.
56. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis 1993; 168:275-81.
57. Flick JA. Does measles really predispose to tuberculosis? Am Rev Respir Dis 1976; 114:257-65.
58. Crosse BA. Subcutaneous and mediastinal emphysema complication of measles [letter]. J Infect 1989; 19:190.
59. Markowitz LE, Nieburg P. The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine. Rev Infect Dis 1991; 13(Suppl 6):S555-61.
60. Sharma A. A rare complication of measles: subcutaneous and mediastinal emphysema. J Trop Med Hyg 1993; 96:169-71.
61. Johnson RT. Inflammatory and demyelinating diseases. In: Johnson RT, ed. Viral infections of the nervous system. 2nd ed. Philadelphia: Lippincott-Raven, 1998:227-64.
62. Cohen N, Golik A, Blatt A, et al. Pancreatic enzyme elevation in measles. J Clin Gastroenterol 1994; 19:292-5.
63. Koster FT, Curlin GC, Aziz KM, Haque A. Synergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh. Bull World Health Organ 1981; 59:901-8.
64. Sommer A. Xerophthalmia, keratomalacia, and nutritional blindness. Int Ophthalmol 1990; 14:195-9.
65. Hudson JB, Weinstein L, Chang TW. Thrombocytopenic purpura in measles. J Pediatr 1956; 48:48-56.
66. Gavish D, Kleinman Y, Morag A, Chajek-Shaul T. Hepatitis and jaundice associated with measles in young adults. An analysis of 65 cases. Arch Intern Med 1983; 143:674-7.
67. Leibovici L, Sharir T, Kalter-Leibovici O, Alpert G, Epstein LM. An outbreak of measles among young adults. Clinical and laboratory features in 461 patients. J Adolesc Health Care 1988; 9:203-7.
68. Wairagkar NS, Gandhi BV, Katrak SM, Shaikh NJ, Parikh PR, Wadia NH, et al. Acute renal failure with neurological involvement in adults associated with measles virus isolation. Lancet 1999; 354:992-5.
69. Casanova-Cardiel LJ, Hermida-Escobedo C. Sarampión en el adulto joven: características clínicas en 201 casos. Rev Invest Clin 1994; 46: 93-8.
70. Atabani SF, Byrnes AA, Jaye A, et al. Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis 2001; 184:1-9.
71. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis 1994; 170(Suppl 1):S24-31.
72. Schneider-Schaulies S, ter Meulen V. Pathogenic aspects of measles virus infections. Arch Virol Suppl 1999; 15:139-58.
73. Butler JC, Havens PL, Sowell AL, et al. Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics 1993; 91:1176-81.
74. Fortenberry JD, Mariscalco MM, Louis PT, Stein F, Jones JK, Jefferson LS. Severe laryngotracheobronchitis complicating measles. Am J Dis Child 1992; 146:1040-3.
75. Makhene MK, Diaz PS. Clinical presentations and complications of suspected measles in hospitalized children. Pediatr Infect Dis J 1993; 12:836-40.
76. Manning SC, Ridenour B, Brown OE, Squires J. Measles: an epidemic of upper airway obstruction. Otolaryngol Head Neck Surg 1991; 105: 415-8.
77. Mason WH, Ross LA, Lanson J, Wright HT Jr. Epidemic measles in the postvaccine era: evaluation of epidemiology, clinical presentation and complications during an urban outbreak. Pediatr Infect Dis J 1993; 12: 42-8.
78. Ross LA, Mason WH, Lanson J, Deakers TW, Newth CJ. Laryngotracheobronchitis as a complication of measles during an urban epidemic. J Pediatr 1992; 121:511-5.
79. Swift JD, Barruga MC, Perkin RM, van Stralen D. Respiratory failure complicating rubeola. Chest 1993; 104:1786-7.
80. Hussey GD, Clements CJ. Clinical problems in measles case management. Ann Trop Paediatr 1996; 16:307-17.
81. Kohn JL, Koiransky H. Successive roentgenograms of the chest of children during measles. Am J Dis Child 1929; 38:258-70.
82. Centers for Disease Control and Prevention. Update: measles outbreak - Chicago, 1989. MMWR Morb Mortal Wkly Rep 1990; 39:317-9, 325-6.
83. Dales LG, Kizer KW, Rutherford GW, Pertowski CA, Waterman SH, Woodford G. Measles epidemic from failure to immunize. West J Med 1993; 159:455-64.
84. Davis RM, Whitman ED, Orenstein WA, Preblud SR, Markowitz LE, Hinman AR. A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol 1987; 126:438-9.
85. Gremillion DH, Crawford GE. Measles pneumonia in young adults. An analysis of 106 cases. Am J Med 1981; 71:539-42.
86. McGrath D, Swanson R, Weems S, Mack D, Barbour SD. Analysis of a measles outbreak in Kent County, Michigan, in 1990. Pediatr Infect Dis J 1992; 11:385-9.
87. Wyll SA, Witte JJ. Measles in previously vaccinated children. An epidemiological study. JAMA 1971; 216:1306-10.
88. Henneman PL, Birnbaumer DM, Cairns CB. Measles pneumonitis. Ann Emerg Med 1995; 26:278-82.
89. Wong RD, Goetz MB. Clinical and laboratory features of measles in hospitalized adults. Am J Med 1993; 95:377-83.
90. Quiambao BP, Gatchalian SR, Halonen P, et al. Coinfection is common in measles-associated pneumonia. Pediatr Infect Dis J 1998; 17: 89-93.
91. Chapnick EK, Gradon JD, Kim YD, et al. Fatal measles pneumonia in an immunocompetent patient - case report. Clin Infect Dis 1992; 15:377-9.
92. Kaschula RO, Druker J, Kipps A. Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor. Rev Infect Dis 1983; 5:395-404.
93. Kipps A, Kaschula RO. Virus pneumonia following measles: a virological and histological study of autopsy material. S Afr Med J 1976; 50: 1083-8.
94. Martin LT, Counahan R, Tait R, Cosgrove JF. Fatal measles giant cell pneumonia. Ir Med J 1982; 75:252-3.
95. Loukides S, Panagou P, Kolokouris D, Kalogeropoulos N. Bacterial pneumonia as a suprainfection in young adults with measles. Eur Respir J 1999; 13:356-60.
96. Yalaburgi SB. Subcutaneous and mediastinal emphysema following respiratory tract complications in measles. S Afr Med J 1980; 58:521-4.
97. Carmena J, Tornero C, Salcedo M, Perpinan J, Pons E. Neumonía por sarampión en embarazada portadora de anticuerpos para el HIV. Respuesta al tratamiento con inmunoglobulinas. Enferm Infecc Microbiol Clin 1996; 14:456-7.
98. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994; 19:454-62.
99. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237-41.
100. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989; 261:2512-6.
101. Lewis MJ, Cameron AH, Shah KJ, Purdham DR, Mann JR. Giant-cell pneumonia caused by measles and methotrexate in childhood leukaemia in remission. Br Med J 1978; 1:330-1.
102. Lipsey AI, Kahn MJ, Bolande RP. Pathologic variants of congenital hypogammaglobulinemia: an analysis of 3 patients dying of measles. Pediatrics 1967; 39:659-74.
103. Markowitz LE, Chandler FW, Roldan EO, et al. Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis 1988; 158:480-3.
104. Nakano T, Shimono Y, Sugiyama K, et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38:212-7.
105. Gray MM, Hann IM, Glass S, Eden OB, Jones PM, Stevens RF. Mortality and morbidity caused by measles in children with malignant, disease attending four major treatment centres: a retrospective review. Br Med J (Clin Res Ed) 1987; 295:19-22.
106. Siegel MM, Walter TK, Ablin AR. Measles pneumonia in childhood leukemia. Pediatrics 1977; 60:38-40.
107. Pancharoen C, Ruttanamongkol P, Suwangool P, Likitnukul S, Thisyakorn U. Measles-associated appendicitis: two case reports and literature review. Scand J Infect Dis 2001; 33:632-3.
108. Searle A, Owen WJ. Measles appendicitis [case report]. Br J Clin Pract 1990; 44:749.
109. Whalen TV, Klos JR, Kovalcik PJ, Cross GH. Measles and appendicitis. Am Surg 1980; 46:412-3.
110. Feachem RG, Koblinsky MA. Interventions for the control of diarrhoeal diseases among young children: measles immunization. Bull World Health Organ 1983; 61:641-52.
111. Greenberg BL, Sack RB, Salazar-Lindo E, et al. Measles-associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. J Infect Dis 1991; 163:495-502.
112. Sang FC, Kangethe SK, Orinda VA, Gatheru Z, Black RE, Waiyaki PG. Escherichia coli associated with acute measles and diarrhoea at Kenyatta National Hospital, Kenya. East Afr Med J 1992; 69:135-9.
113. Varavithya W, Aswasuwana S, Phuapradit P, Louisirirotchanakul S, Supavej S, Nopchinda S. Etiology of diarrhea in measles. J Med Assoc Thai 1989; 72:151-4.
114. Chavez GF, Ellis AA. Pediatric hospital admissions for measles. Lessons from the 1990 epidemic. West J Med 1996; 165:20-5.
115. Morley D. Severe measles in the tropics. I. Br Med J 1969; 1:297-300.
116. Commey JO, Richardson JE. Measles in Ghana - 1973-1982. Ann Trop Paediatr 1984; 4:189-94.
117. Enwonwu CO, Falkler WA Jr, Idigbe EO, Savage KO. Noma (cancrum oris): questions and answers. Oral Dis 1999; 5:144-9.
118. Hendrickse RG, Sherman PM. Morbidity and mortality from measles in children seen at University College Hospital, Ibadan. Arch Virusforsch 1965; 16:27-34.
119. Krishnamurthy KA, Anantharaman V. Measles - a dangerous disease: a study of 1000 cases in Madurai. Indian Pediatr 1974; 11:267-71.
120. Ackerman Z, Ackerman E, Shouval D. Measles: clinical and laboratory observations in young adults during an epidemic. South Med J 1988; 81:1396-400.
121. Giladi M, Schulman A, Kedem R, Danon YL. Measles in adults: a prospective study of 291 consecutive cases. Br Med J (Clin Res Ed) 1987; 295:1314.
122. Morcos NC, McHugh H. Pancreatitis associated with measles in a young adult. J Natl Med Assoc 1997; 89:435, 437.
123. Mouallem M, Friedman E, Pauzner R, Farfel Z. Measles epidemic in young adults. Clinical manifestations and laboratory analysis in 40 patients. Arch Intern Med 1987; 147:1111-3.
124. Miller DL. Frequency of complications of measles, 1963: report on a national inquiry by the Public Health Laboratory Service in collaboration with the Society of Medical Officers of Health. Br Med J 1964; 5401:75-8.
125. Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the Medical Research Council by the Measles Vaccines Committee. Br Med J 1968; 2:449-52.
126. Vaccination against measles. Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Third report to the Medical Research Council by the Measles Vaccines Committee. Practitioner 1971; 206:458-66.
127. Centers for Disease Control. Measles - Los Angeles County, California, 1988. MMWR Morb Mortal Wkly Rep 1989; 38:49-52, 57.
128. Gibbs FA, Gibbs EL, Carpenter PR, Spies HW. Electroencephalographic abnormality in "uncomplicated" childhood diseases. JAMA 1959; 171: 1050-5.
129. Hanninen P, Arstila P, Lang H, Salmi A, Panelius M. Involvement of the central nervous system in acute, uncomplicated measles virus infection. J Clin Microbiol 1980; 11:610-3.
130. Pampiglione G. Prodromal phase of measles: some neurophysiological studies. Br Med J 1964; :1296-300.
131. Miller HG, Stanton JB, Gibbons JL. Para-infectious encephalomyelitis and related syndromes: a critical review of the neurological complications of certain specific fevers. Q J Med 1956; 25:427-505.
132. Bloch AB, Orenstein WA, Wassilak SG, et al. Epidemiology of measles and its complications. In: Gruenberg E, Lewis C, Goldston SE, eds. Vaccinating against brain syndromes: the campaign against measles and rubella. New York: Oxford University Press, 1986:5-20.
133. Miller CL. Severity of notified measles. Br Med J 1978; 1:1253.
134. Boughton CR. Morbilli in Sydney. Part II. Neurological sequelae of morbilli. Med J Aust 1964; 212:908-15.
135. ter Meulen V, Muller D, Kackell Y, Katz M, Meyermann R. Isolation of infectious measles virus in measles encephalitis. Lancet 1972; 2: 1172-5.
136. Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis - clinical and immunologic studies. N Engl J Med 1984; 310:137-41.
137. Tellez-Nagel I, Harter DH. Subacute sclerosing leukoencephalitis. I. Clinico-pathological, electron microscopic and virological observations. J Neuropathol Exp Neurol 1966; 25:560-81.
138. Ohuchi M, Ohuchi R, Mifune K, Ishihara T, Ogawa T. Characterization of the measles virus isolated from the brain of a patient with immunosuppressive measles encephalitis. J Infect Dis 1987; 156:436-41.
139. Centers for Disease Control. Subacute sclerosing panencephalitis surveillance-United States. MMWR Morb Mortal Wkly Rep 1982; 31: 585-8.
140. Detels R, Brody JA, McNew J, Edgar AH. Further epidemiological studies of subacute sclerosing panencephalitis. Lancet 1973; 2:11-4.
141. Halsey NA, Modlin JF, Jabbour JT, Dubey L, Eddins DL, Ludwig DD. Risk factors in subacute sclerosing panencephalitis: a case-control study. Am J Epidemiol 1980; 111:415-24.
142. Halsey NA, Modlin JF, Jabbour JT. Subacute sclerosing panencephalitis (SSPE): an epidemiologic review. In: Stevens JG, Todaro GJ, Fox CF, eds. Persistent viruses. New York: Academic Press, 1978; 101-14.
143. Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977; 59:505-12.
144. Yalaz K, Anlar B, Renda Y, Aysun S, Topcu M, Ozdirim E. Subacute sclerosing panencephalitis in Turkey: epidemiological features. J Trop Pediatr 1988; 34:301-5.
145. Aicardi J, Goutieres F, Arsenio-Nunes ML, Lebon P. Acute measles encephalitis in children with immunosuppression. Pediatrics 1977; 59:232-9.
146. Colamaria V, Marradi P, Merlin D, et al. Acute measles encephalitis of the delayed type in an immunosuppressed child. Brain Dev 1989; 11: 322-6.
147. Hughes I, Jenney ME, Newton RW, Morris DJ, Klapper PE. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 68:775-8.
148. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993; 16:654-60.
149. Kayikcioglu O, Kir E, Soyler M, Guler C, Irkec M. Ocular findings in a measles epidemic among young adults. Ocul Immunol Inflamm 2000; 8:59-62.
150. Foster A, Sommer A. Childhood blindness from corneal ulceration in Africa: causes, prevention, and treatment. Bull World Health Organ 1986; 64:619-23.
151. Foster A, Sommer A. Corneal ulceration, measles, and childhood blindness in Tanzania. Br J Ophthalmol 1987; 71:331-43.
152. Ohara Y. Multiple sclerosis and measles virus. Jpn J Infect Dis 1999; 52: 198-200.
153. Halsey NA, Hyman SL. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000 [review]. Pediatrics 2001; 107:E84.
154. Stratton K, Gable A, Shetty P, McCormick M. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press, 2001.
155. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324:393-6.
156. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 2001; 22:249-57.
157. Niedermeyer HP, Arnold W, Neubert WJ, Sedlmeier R. Persistent measles virus infection as a possible cause of otosclerosis: state of the art. Ear Nose Throat J 2000; 79:552-4, 556, 558 passim.
158. Reddy SV, Menaa C, Singer FR, et al. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol 1999; 27:1528-32.
159. Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J Med Virol 2000; 62:377-82.
160. Wakefield AJ, Montgomery SM. Measles virus as a risk for inflammatory bowel disease: an unusually tolerant approach. Am J Gastroenterol 2000; 95:1389-92.
161. Aaby P, Oesterle H, Dietz K, Becker N. Case-fatality rates in severe measles outbreak in rural Germany in 1861. Lancet 1992; 340:1172.
162. Garenne M. Sex differences in measles mortality: a world review. Int J Epidemiol 1994; 23:632-42.
163. Barkin RM. Measles mortality: a retrospective look at the vaccine era. Am J Epidemiol 1975; 102:341-9.
164. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992; 14:217-26.
165. Celers J. Problèmes de Santé Publique posés par la rougeole dans les pays favorisés. Arch Virusforsch 1965; 16:5-18.
166. Christensen PE, Schmidt H, Bang HO, Andersen V, Jordal B, Jensen O. An epidemic of measles in southern Greenland, 1951. Measles in virgin soil. II. The epidemic proper. Acta Med Scand 1953; 144:450-49.
167. Cliff AD, Haggett P, Smallman-Raynor M. Measles: an historical geography of a major human viral disease from global expansion to local retreat, 1840-1990. Oxford, UK: Blackwell, 1993.
168. Peart AFW, Nagler FP. Measles in the Canadian arctic, 1952. Can J Public Health 1954; 45:146-57.
169. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000; 31:578-85.
170. Khanna KV, Markham RB. A perspective on cellular immunity in the elderly. Clin Infect Dis 1999; 28:710-3.
171. Aaby P, Coovadia H. Severe measles: a reappraisal of the role of nutrition, overcrowding, and virus dose. Med Hypotheses 1985; 18:93-112.
172. Aaby P. Malnutrition and overcrowding/intensive exposure in severe measles infection: review of community studies. Rev Infect Dis 1988; 10:478-91.
173. Aaby P, Bukh J, Lisse IM, Smits AJ. Severe measles in Sunderland, 1885: a European-African comparison of causes of severe infection. Int J Epidemiol 1986; 15:101-7.
174. Burstrom B, Diderichsen F, Smedman L. Child mortality in Stockholm during 1885-1910: the impact of household size and number of children in the family on the risk of death from measles. Am J Epidemiol 1999; 149:1134-41.
175. Koenig MA, Bishai D, Khan MA. Health interventions and health equity: the example of measles vaccination in Bangladesh. Popul Dev Rev 2001; 27:283-302.
176. Butler JC, Proctor ME, Fessier K, Hopfensperger DJ, Sosin DM, Davis JP. Household-acquisition of measles and illness severity in an urban community in the United States. Epidemiol Infect 1994; 112:569-77.
177. Sutter RW, Markowitz LE, Bennetch JM, Morris W, Zell ER, Preblud SR. Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. J Infect Dis 1991; 163: 12-6.
178. American Academy of Pediatrics. Immunization in special clinical circumstances: immunocompromised children. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:56-67.
179. Buescher ES. Infectious complications of dysfunction/deficiency of polymorphonuclear and mononuclear phagocytes. In: Long SS, Pickering LK, Prober CG, eds. Principles and practices of pediatric infectious diseases. New York: Churchill Livingstone, 1997:715-24.
180. Patrick CC, Slobod KS. Opportunistic infections in the compromised host. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 4th ed. Philadelphia: WB Saunders, 1998:980-94.
181. Breitfeld V, Hashida Y, Sherman FE, Odagiri K, Yunis EJ. Fatal measles infection in children with leukemia. Lab Invest 1973; 28:279-91.
182. Mitus A, Enders JF, Craig JM, Holloway A. Persistence of measles virus and depression of antibody formation in patients with giant-cell pneumonia after measles. N Engl J Med 1959; 261:882-9.
183. Vargas PA, Bernardi FD, Alves VA, et al. Uncommon histopathological findings in fatal measles infection: pancreatitis, sialoadenitis, and thyroiditis. Histopathology 2000; 37:141-6.
184. de Moraes-Pinto MI, Farhat CK, Carbonare SB, et al. Maternally acquired immunity in newborns from women infected by the human immunodeficiency virus. Acta Paediatr 1993; 82:1034-8.
185. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis 1992; 165:262-7.
186. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999; 29:106-12.
187. Friedman S. Measles in New York City [letter]. JAMA 1991; 266:1220.
188. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008-14.
189. Sension MG, Quinn TC, Markowitz LE, et al. Measles in hospitalized African children with human immunodeficiency virus. Am J Dis Child 1988; 142:1271-2.
190. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4.
191. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-4.
192. Chen LC, Rahman M, Sarder AM. Epidemiology and causes of death among children in a rural area of Bangladesh. Int J Epidemiol 1980; 9: 25-33.
193. Smedman L, Lindeberg A, Jeppsson O, Zetterstrom R. Nutritional status and measles: a community study in Guinea-Bissau. Ann Trop Paediatr 1983; 3:169-76.
194. Dossetor J, Whittle HC, Greenwood BM. Persistent measles infection in malnourished children. Br Med J 1977; 1:1633-5.
195. Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985; 313:544-9.
196. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160-4.
197. Sommer A, West KP. Vitamin A deficiency: health, survival, and vision. New York: Oxford University Press, 1996.
198. Hatun S, Tezic T, Kunak B, Cengiz AB. Vitamin A levels of children with measles in Ankara, Turkey. Turk J Pediatr 1995; 37:193-200.
199. Arrieta AC, Zaleska M, Stutman HR, Marks MI. Vitamin A levels in children with measles in Long Beach, California. J Pediatr 1992; 121: 75-8.
200. Frieden TR, Sowell AL, Henning KJ, Huff DL, Gunn RA. Vitamin A levels and severity of measles. New York City. Am J Dis Child 1992; 146:182-6.
201. Barclay AJ, Foster A, Sommer A. Vitamin A supplements and mortality related to measles: a randomised clinical trial. Br Med J (Clin Res Ed) 1987; 294:294-6.
202. D'Souza RM, D'Souza R. Vitamin A for the treatment of children with measles - a systematic review. J Trop Pediatr 2002; 48:323-7.
203. D'Souza RM, D'Souza R. Vitamin A for preventing secondary infections in children with measles - a systematic review. J Trop Pediatr 2002; 48:72-7.
204. Expanded Programme on Immunization. Joint WHO/UNICEF statement on vitamin A for measles. Wkly Epidemiol Rec 1987; 62:133-4.
205. American Academy of Pediatrics. Measles. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:385-96.
206. Ellison JB. Pneumonia in measles. Arch Dis Child 1931; 6:37-51.
207. Swyer R. The use of sulphonamides in measles. Br J Child Dis 1943; 40: 63-7.
208. Cliff AD, Haggett P, Smallman-Raynor M. Measles: an historical geography of a major human viral disease from global expansion to local retreat, 1840-1990. Oxford, UK: Blackwell, 1993.
209. United States Public Health Service. Prevalence of communicable diseases. Public Health Rep 1914; 29:111-27.
210. United States Public Health Service. Vital statistics rates in the United States, 1900-1940. Washington, DC: US Public Health Service, 1947. Available at: http://www.cdc.gov/nchs/data/vsus/vsrates1900_40.pdf. Accessed 5 March 2004.
211. Communicable Disease Center. Reported incidence of notifiable diseases in the United States, 1962. MMWR Morb Mortal Wkly Rep 1962; 11: 4-5.
212. Hinman AR. Resurgence of measles in New York. Am J Public Health 1972; 62:498-503.
213. Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania MJ. Acute measles mortality in the United States, 1987-2002. J Infect Dis 2004; 189(Suppl 1):S69-77.
214. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-42.
215. Aaby P, Clements CJ. Measles immunization research: a review. Bull World Health Organ 1989; 67:443-8.
216. Aaby P. Determinants of measles mortality: host or transmission factors? In: de la Maza LM, Peterson EM, eds. Medical virology 10: proceedings of the 10th International Symposium on Medical Virology. 10th ed. New York: Plenum Press, 1991:83-116.
217. Omer MI. Measles: a disease that has to be eradicated. Ann Trop Paediatr 1999; 19:125-34.
218. WHO-UNICEF joint statement on strategies to reduce measles mortality worldwide. Geneva: World Health Organization, 2001:1-4.
219. Jones G, Steketee RW, Black KE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet 2003; 362:65-71.
220. Morris SS, Black RE, Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003; 32:1041-51.
221. Black FL. Measles antibody prevalence in diverse populations. Am J Dis Child 1962; 103:242-9.
222. Foege WH, Foster SO. Multiple antigen vaccine strategies in developing countries. Am J Trop Med Hyg 1974; 23:685-9.
223. Marufu T, Siziya S, Murugasampillay S, Mason E, Manyame B, Tshimanga M. Measles complications: the importance of their management in reducing mortality attributed to measles. Cent Afr J Med 1997; 43: 162-5.
224. Bhaskaram P, Balakrishna N, Goud BN, Sukanya M. Post-vaccination scenario of measles: a retrospective analysis. Natl Med J India 1999; 12: 111-2.
225. Bilkis MD, Barrero PR, Mistchenko AS. Measles resurgence in Argentina: 1997-8 outbreak. Epidemiol Infect 2000; 124:289-93.
226. Garenne M, Kahn K, Tollman S, Gear J. Causes of death in a rural area of South Africa: an international perspective. J Trop Pediatr 2000; 46:183-90.
227. Marufu T, Siziya S. Secular changes in rates of respiratory complications and diarrhoea among measles cases. J Trop Pediatr 1998; 44: 347-50.
228. Taylor WR. Measles in Vietnamese refugee children in Hong Kong. Epidemiol Infect 1999; 122:441-6.
229. Hersh BS, Tambini G, Nogueira AC, Carrasco P, de Quadros CA. Review of regional measles surveillance data in the Americas, 1996-99. Lancet 2000; 355:1943-8.
230. Biellik R, Madema S, Taole A, et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 2002; 359:1564-8.
231. Salama P, Assefa F, Talley L, Spiegel P, van Der Veen A, Gotway CA. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. JAMA 2001; 286:563-71.
232. Wakeham PF. Severe measles in Afghanistan. J Trop Pediatr Environ Child Health 1978; 24:87-8.
233. Ahmad K. Measles epidemic sweeps through Afghanistan. Lancet 2000; 355:1439.
234. Boughton CR. Morbilli in Sydney: a review of 3601 cases with consideration of morbidity, mortality, and measles encephalitis. Med J Aust 1964; 58:859-65.
235. Hatziandreu EJ, Brown RE, Halpern MT. A cost-benefit analysis of the measles-mumps-rubella (MMR) vaccine. Arlington, VA: Battelle Medical Technology Assessment and Policy Research Program, 1994:1-65.
236. Koplan JP, White CC. An update on the benefits and costs of measles and rubella immunization. In: Gruenberg E, Lewis C, Goldston SE, eds. Vaccinating against brain syndromes: the campaign against measles and rubella. New York: Oxford University Press, 1986:117-27.
237. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps, and rubella. Am J Public Health 1985; 75:739-44.
238. Clemens JD, Stanton BF, Chakraborty J, et al. Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988; 128:1330-9.
239. Holt EA, Boulos R, Halsey NA, Boulos LM, Boulos C. Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics 1990; 85:188-94.
240. Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995; 311:481-5.
241. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 2000; 321: 1435-8.